DRKS00011639RecruitingPhase 3
Patients with Multiple Sclerosis and Severe Disabilities: Effects of Electrical Stimulation Cycling Training on Mobility an Power Performance
Zentrum für Sensomotorik der Neurologischen Klinik,Klinikum Großhadern0 sites64 target enrollmentStarted: February 20, 2017Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- Enrollment
- 64
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized controlled study
- Masking
- Blinded (masking used)
Eligibility Criteria
- Ages
- 18 Years to one (—)
- Sex
- All
Inclusion Criteria
- •Diagnosis: Multiple Sklerosis
- •-Age > 18 y
- •-Reduced lower extremity muscle function, Gait impairment
Exclusion Criteria
- •-having power of attorney
- •-no pacemaker or higher-grade arrhythmias
- •-no metall parts in the stimulation area
- •-no skin allergia against electrodes
- •-no wound or other lesions in the stimulation area
- •-no osteoporosis, no muscle or ligament contractures, no reduced range of motion in the knee and hip joints.
Investigators
Similar Trials
Recruiting
Phase 1
For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment on the absence of radiological disease activity at 2 years: a multicentre randomised controlled non-inferiority trialMultiple sclerosisCTIS2023-505420-62-00Hopital Fondation Adolphe De Rothschild192
Not yet recruiting
Phase 3
Treatment of Progressive Multiple Sclerosis-related Cognitive Impairment, Fatigue, and Depression Using Repetitive Transcranial Magnetic StimulatioNervous System DiseasesPACTR202403516079512Science Technology and Innovation Funding Authority60
Completed
Not Applicable
Diagnostic criteria for Multiple Sclerosis: Impact of high field Magnetic Resonance Imagingmultiple sclerosisMS1000381610012303NL-OMON40083Vrije Universiteit Medisch Centrum30
Completed
Phase 2
MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation TrialSecondary Progressive Multiple SclerosisNCT01910259University College, London445
Completed
Phase 3
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MSSpasticity, MuscleMultiple SclerosisNCT03290131RVL Pharmaceuticals, Inc.536